NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Sensei Biotherapeutics, Inc. (SNSE) Stock Analysis

Sensei Biotherapeutics, Inc. (SNSE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SNSE

$25.96

+$9.49 (+57.62%)

Last trade July 17, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNSE with… →

SNSE Key Statistics

As of Jul 17, 2026
Trading
Open
$24.52
Previous Close
$16.47
Day's Range
23.82–26.22
52-Week Range
5.32–36.76
Volume
98.56K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.18
Valuation
Market Cap
$22.10M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−142.72
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$21.09M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+223.69%
Dividend and dates
Avg Volume
63.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNSE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+143.30%
2025+0.66%

As of July 17, 2026.

SNSE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$21.09M—
2024$0.00−$30.16M—
2023$0.00−$34.10M—
2022$0.00−$48.59M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$22.29M−$21.09M—
2024$0.00—−$31.66M−$30.16M—
2023$0.00—−$37.06M−$34.10M—
2022$0.00—−$50.19M−$48.59M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SNSE Valuation vs Biotechnology Median

Median of 656 stocks
MetricSNSEBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Sensei Biotherapeutics, Inc. (SNSE) is capitalised at $22.10M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 29.

The most recent close on file for SNSE is $25.96, dated July 17, 2026. That is +$9.49 (+57.62%) against the previous close. The 52-week range on file runs from $5.32 to $36.76. The latest close sits 387.97% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $21.09M. Profit margin runs at 0%. Trailing earnings per share are −142.72.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +223.69%. The stored price history starts on January 13, 2025, and the total return since then is +144.91%. The reported beta is −0.18. Daily returns over the trailing 1 year annualize to a volatility of 242.3%.

Growth & Income

The record shows no dividend for SNSE.

So far in 2026 the price is +143.30%. The record holds one complete calendar year, 2025, which returned +0.66%.

Peer Comparison

Sensei Biotherapeutics, Inc. (SNSE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sensei Biotherapeutics, Inc. SNSE $22.10M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sensei Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 17, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Visit website →